OPKO Health Dirección

Dirección controles de criterios 2/4

El CEO de OPKO Health es Phil Frost , nombrado en Mar 2007, tiene una permanencia de 17.67 años. compensación anual total es $2.28M, compuesta por 42.2% salario y 57.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 35.94% de las acciones de la empresa, por valor de $382.68M. La antigüedad media del equipo directivo y de la junta directiva es de 9.7 años y 15.6 años, respectivamente.

Información clave

Phil Frost

Chief Executive Officer (CEO)

US$2.3m

Compensación total

Porcentaje del salario del CEO	42.2%
Permanencia del CEO	17.7yrs
Participación del CEO	35.9%
Permanencia media de la dirección	9.7yrs
Promedio de permanencia en la Junta Directiva	15.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Phil Frost en comparación con los beneficios de OPKO Health?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$134m
Jun 30 2024	n/a	n/a	-US$243m
Mar 31 2024	n/a	n/a	-US$252m
Dec 31 2023	US$2m	US$960k	-US$189m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$209m
Mar 31 2023	n/a	n/a	-US$291m
Dec 31 2022	US$972k	US$960k	-US$328m
Sep 30 2022	n/a	n/a	-US$317m
Jun 30 2022	n/a	n/a	-US$202m
Mar 31 2022	n/a	n/a	-US$117m
Dec 31 2021	US$2m	US$960k	-US$30m
Sep 30 2021	n/a	n/a	US$76m
Jun 30 2021	n/a	n/a	US$71m
Mar 31 2021	n/a	n/a	US$121m
Dec 31 2020	US$2m	US$960k	US$31m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$200m
Mar 31 2020	n/a	n/a	-US$293m
Dec 31 2019	US$1m	US$960k	-US$315m
Sep 30 2019	n/a	n/a	-US$279m
Jun 30 2019	n/a	n/a	-US$244m
Mar 31 2019	n/a	n/a	-US$191m
Dec 31 2018	US$2m	US$960k	-US$153m
Sep 30 2018	n/a	n/a	-US$295m
Jun 30 2018	n/a	n/a	-US$303m
Mar 31 2018	n/a	n/a	-US$314m
Dec 31 2017	US$971k	US$960k	-US$305m

Compensación vs. Mercado: La compensación total de Phil($USD2.28M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD1.48M).

Compensación vs. Ingresos: La compensación de Phil ha aumentado mientras la empresa no es rentable.

CEO

Phil Frost (88 yo)

17.7yrs

Permanencia

US$2,277,200

Compensación

Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Phillip Frost	Chairman & CEO	17.7yrs	US$2.28m	35.94% $ 382.7m
Jane Hsiao	Vice Chairman & Chief Technical Officer	17.8yrs	US$2.19m	4.85% $ 51.7m
Elias Zerhouni	President & Vice Chairman	2.5yrs	US$2.19m	2.99% $ 31.9m
Adam Logal	Senior VP	17.7yrs	US$1.81m	0.026% $ 279.5k
Steven Rubin	Executive VP of Administration & Director	17.5yrs	US$1.94m	0.91% $ 9.7m
Akhtar Ashfaq	Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal	7.7yrs	sin datos	sin datos
Gary Nabel	Chief Innovation Officer & Director	2.5yrs	sin datos	5.91% $ 62.9m
Giovanni Abbadessa	Chief Medical Officer	less than a year	sin datos	sin datos
Charles Bishop	Chief Executive Officer of OPKO Renal	11.7yrs	sin datos	sin datos
Antonio Cruz	President of Transition Therapeutics	no data	sin datos	sin datos
Hans Berner	President of OPKO Health Iberoamerica	no data	sin datos	sin datos
Damien Burke	Chief Executive Officer of EirGen Pharma	5yrs	sin datos	sin datos

9.7yrs

Permanencia media

71.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0KCS es experimentado (9.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Phillip Frost	Chairman & CEO	17.7yrs	US$2.28m	35.94% $ 382.7m
Jane Hsiao	Vice Chairman & Chief Technical Officer	17.8yrs	US$2.19m	4.85% $ 51.7m
Elias Zerhouni	President & Vice Chairman	2.5yrs	US$2.19m	2.99% $ 31.9m
Steven Rubin	Executive VP of Administration & Director	17.8yrs	US$1.94m	0.91% $ 9.7m
Gary Nabel	Chief Innovation Officer & Director	2.5yrs	sin datos	5.91% $ 62.9m
Roger Medel	Independent Director	3.9yrs	US$69.90k	0% $ 0
Richard Pfenniger	Lead Independent Director	16.8yrs	US$134.80k	0.048% $ 507.0k
Richard Krasno	Independent Director	7.8yrs	US$92.40k	0.015% $ 161.2k
John Paganelli	Independent Director	20.9yrs	US$84.90k	0.058% $ 613.9k
Prem Lachman	Independent Director	3.7yrs	US$92.40k	0% $ 0
Lin-Tsing Yu	Independent Director	15.6yrs	US$62.40k	0.0097% $ 103.7k

15.6yrs

Permanencia media

77yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 0KCS son experimentados ( 15.6 años antigüedad media).

OPKO Health Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chairman & CEO recently bought US$422k worth of stock

Chairman & CEO recently bought US$127k worth of stock

Chairman & CEO recently bought US$992k worth of stock

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought US$1.5m worth of stock

President & Vice Chairman recently bought US$514k worth of stock

Recent updates

Chairman & CEO recently bought US$422k worth of stock

OPKO Health, Inc. Provides Financial Guidance for the Fourth Quarter 2024

Third quarter 2024 earnings released: EPS: US$0.036 (vs US$0.11 loss in 3Q 2023)

OPKO Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.015 loss per share (vs US$0.026 loss in 2Q 2023)

OPKO Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares.

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Chairman & CEO recently bought US$127k worth of stock

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

OPKO Health, Inc. announced delayed annual 10-K filing

New major risk - Financial position

No longer forecast to breakeven

Full year 2023 earnings released: US$0.25 loss per share (vs US$0.46 loss in FY 2022)

New major risk - Revenue and earnings growth

Chairman & CEO recently bought US$992k worth of stock

OPKO Health, Inc. to Report Q4, 2023 Results on Feb 27, 2024

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought US$1.5m worth of stock

President & Vice Chairman recently bought US$514k worth of stock

New minor risk - Profitability

Chairman & CEO recently bought US$1.3m worth of stock

New minor risk - Profitability

OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol

OPKO Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chairman & CEO recently bought US$1.2m worth of stock

Second quarter 2023 earnings released: US$0.026 loss per share (vs US$0.14 loss in 2Q 2022)

OPKO Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Profitability

Chief Innovation Officer & Director recently bought US$541k worth of stock

First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.084 loss in 1Q 2022)

Chairman & CEO recently bought US$264k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.047 loss in FY 2021)

OPKO Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chairman & CEO recently bought US$447k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.044 profit in 3Q 2021)

OPKO Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chairman & CEO recently bought US$133k worth of stock

Chairman & CEO recently bought US$413k worth of stock

Chairman & CEO recently bought US$214k worth of stock

Chairman & CEO recently bought US$508k worth of stock

OPKO Health, Inc. Announces Leadership Changes for Bioreference Laboratories

Chairman & CEO recently bought US$802k worth of stock

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.025 loss in 2Q 2021)

OPKO Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

OPKO Health, Inc., Annual General Meeting, Jul 14, 2022

Chairman & CEO recently bought US$1.1m worth of stock

First quarter 2022 earnings released: US$0.084 loss per share (vs US$0.048 profit in 1Q 2021)

OPKO Health, Inc. (NasdaqGS:OPK) acquired ModeX Therapeutics, Inc. for $300 million.

OPKO Health, Inc. to Report Q1, 2022 Results on May 09, 2022

Chairman & CEO recently bought US$106k worth of stock

Chairman & CEO recently bought US$2.3m worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Chairman & CEO recently bought US$304k worth of stock

OPKO Health, Inc. to Report Q4, 2021 Results on Feb 24, 2022

OPKO Health, Inc. Announces That Vifor Fresenius Medical Care Renal Pharma has Initiated the Commercial Launch of Rayaldee® in Germany

Chairman & CEO recently bought US$1.0m worth of stock

Investor sentiment deteriorated over the past week

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

Sema4 Holdings Corp. (NasdaqGS:SMFR) entered into an agreement to acquire GeneDx, Inc. from OPKO Health, Inc. (NasdaqGS:OPK) for approximately $620 million.

OPKO Health, Inc. Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

Investor sentiment improved over the past week

Opko Health Receives U.S. FDA Approval for the 4Kscore Test

Investor sentiment improved over the past week